From Cancer Detection to Treatment:

MagnetoTheranostics

MagnetoTheranostics RTD 2013

M. Mionic1, B. von Rechenberg2, H. Thöny3, M. Stuber4, O. Jordan5, N. Kuster6, H. Hofmann1

1 EPFL, 2 University of Zurich, 3 Inselspital, 4 CHUV, 5 University of Geneva, 6 It’IS

Space for your

institution(s) logo(s) (or below the affiliation

list if necessary)

Poster content

(Style and layout is free here)

Note:

If you prefer using another software to prepare your poster, you can of course do so.

In that case, please try and make sure to have it look as close as possible to the present template.

Existing and New Particle composition

Functionalisation of Particle withAntibodies

CharacterisationTox screening

In vitro testsSpecific adsorption

Metastasis

Nanocompositeformulation

In vitro tests Heatingcapacity

In vivo tests tumor

treatment

In vivo tests metastasisdetection

In vivo testsTheragnosis

Improvementof mag

Generator

DevelopmentTemp.

Simulation tool

Engineering ; ITIS, ANTIA

Physics, chemistry Materialscience; EPFL, UNI GE, CHUV

In-vitro, Toxicity, imagingEPFL, ITIS, UNI GE, CHUV

Medical applicationCABMM, Inselspital

Toxi

city

Test

s

Project layout

Mo

lec

ula

r Im

ag

ing

(MR

I)

Hy

pe

rth

erm

ia

Dr. E. Neufeld

Dr. M. H. Capstick

Prof. Dr. Niels Kuster Dr. Olivier Jordan

Prof. Dr. Matthias Stuber

Prof. Dr. HeinrichHofmann

Prof. Dr. med. Harriet Thoeny

Prof. Dr. med. vet.Brigitte von Rechenberg

Prof. Dr. Daniel A. Rüfenacht

Team and competences

Engineering Physics, Material science;

In-vitro, Toxicity, Imaging Medical applications

therapeutics + diagnostics => Theranostics

AIM: Early detection (by MRI) and treatment (by hyperthermia) of lymph node metastases of prostata cancer